Evaluation of antiviral treatment response on liver histopathology in chronic hepatitis B infection patients

References (1)

1. Ormeci N, Ozbas B, Guner R, et al. Tenofovir–best hope for treat-ment of chronic hepatitis B infection? Turk J Gastroenterol 2015; 26: 322-7. [CrossRef ] 2. Calvaruso V, Crax A. Regression of fibrosis after HBV antiviral ther-apy. Is cirrhosis reversible? Liver International 2014; 34(Suppl): 85-90. [CrossRef ] 3. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy re-sults in the reversal of fibrosis/cirrhosis and continued histologi-cal improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93. [CrossRef ] 4. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treat-ment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-75. [CrossRef ] 5. Buti M, Fung F, Gane E, et al. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int 2015; 9: 243-50. [CrossRef